Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

25.27USD
1:30am IST
Change (% chg)

$-0.53 (-2.05%)
Prev Close
$25.80
Open
$25.58
Day's High
$25.74
Day's Low
$25.05
Volume
138,723
Avg. Vol
279,394
52-wk High
$43.98
52-wk Low
$13.51

Chart for

About

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $520.30
Shares Outstanding(Mil.): 22.51
Dividend: --
Yield (%): --

Financials

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

19 Apr 2018

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

15 Mar 2018

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​

12 Mar 2018

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

23 Feb 2018

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

23 Jan 2018

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

09 Jan 2018

Earnings vs. Estimates